STOCK TITAN

Eloxx (NASDAQ: ELOX) director gains shares via RSUs and option grant

Filing Impact
(Neutral)
Filing Sentiment
(Neutral)
Form Type
4

Rhea-AI Filing Summary

Eloxx Pharmaceuticals director Steven D. Rubin reported routine equity compensation activity. On January 24, 2026, he exercised 1,875 restricted stock units (RSUs), receiving an equal number of common shares at $0.00 per share, lifting his direct common stock holdings to 14,625 shares.

Following this RSU conversion, Rubin still held 1,875 RSUs. Earlier, on September 19, 2025, he received a grant of 179,854 stock options for common stock at a $0.15 exercise price, vesting 1/36 on October 31, 2025, then in equal monthly installments over 35 months until September 2035.

Positive

  • None.

Negative

  • None.
Insider Rubin Steven D
Role null
Type Security Shares Price Value
Exercise Restricted Stock Units 1,875 $0.00 --
Exercise Common Stock 1,875 $0.00 --
Grant/Award Stock Option (Right to Buy) 179,854 $0.00 --
Holdings After Transaction: Restricted Stock Units — 1,875 shares (Direct, null); Common Stock — 14,625 shares (Direct, null); Stock Option (Right to Buy) — 179,854 shares (Direct, null)
Footnotes (1)
  1. Each restricted stock unit ("RSU") represents a contingent right to receive one share of the Issuer's common stock. The stock option vested as to 1/36 on October 31, 2025, with the remaining options vesting thereafter in equal consecutive monthly increments for 35 months, subject to the Reporting Person's continuous service to the Issuer through the applicable vesting date. The RSUs vested as to 50% on the first anniversary of January 24, 2024 and the remaining amount vested in two equal annual installments thereafter.
RSUs exercised 1,875 shares Common stock received on January 24, 2026
Common shares held 14,625 shares Direct holdings after January 24, 2026 transaction
RSUs remaining 1,875 units Restricted Stock Units outstanding after conversion
Stock options granted 179,854 options Grant on September 19, 2025 for common stock
Option exercise price $0.15 per share Conversion or exercise price for 179,854 options
Option expiration September 19, 2035 Expiration date of 179,854 stock options
Initial option vesting fraction 1/36 First tranche vested on October 31, 2025
Restricted Stock Units financial
"The RSUs vested as to 50% on the first anniversary of January 24, 2024"
Restricted stock units are a type of company reward where employees are promised shares of stock, but they only fully own these shares after meeting certain conditions, like staying with the company for a set time. They matter because they can become valuable assets and are often used to motivate employees to help the company succeed.
stock option financial
"The stock option vested as to 1/36 on October 31, 2025"
A stock option is a contract that gives you the right to buy or sell a company's stock at a specific price within a certain time frame. People use them to potentially make money if the stock's price moves favorably or to protect against losses. It's like holding a coupon that can be used to buy or sell stock at a set price later on.
exercise price financial
"conversion_or_exercise_price": "0.1500""
The exercise price is the fixed amount at which you can buy or sell an asset, like a stock, when using an options contract. It matters because it helps determine whether exercising the option will be profitable or not, depending on the current market price. Think of it as the set price you agree on today to buy or sell later.
vesting financial
"with the remaining options vesting thereafter in equal consecutive monthly increments"
Vesting is the process by which you earn full ownership of something, like company stock or a retirement benefit, over time. It’s like earning the right to keep a gift piece by piece the longer you stay with a company, making sure employees stay committed before they receive all the benefits.
Form 4 regulatory
"INSIDER FILING DATA (Form 4):"
Form 4 is a official document that company insiders, such as executives or major shareholders, file with regulators whenever they buy or sell company shares. It provides transparency about how those with inside knowledge are trading, helping investors see if insiders are confident in the company's prospects or may be selling for personal reasons. This information can influence investor decisions by revealing insiders' perspectives on the company's value.
SEC Form 4
FORM 4UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940
OMB APPROVAL
OMB Number:3235-0287
Estimated average burden
hours per response:0.5
Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).
Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.
1. Name and Address of Reporting Person*
Rubin Steven D

(Last)(First)(Middle)
C/O ELOXX PHARMACEUTICALS, INC.
P.O. BOX 274

(Street)
ARLINGTON MASSACHUSETTS 02476

(City)(State)(Zip)

UNITED STATES

(Country)
2. Issuer Name and Ticker or Trading Symbol
Eloxx Pharmaceuticals, Inc. [ ELOX ]
5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)
XDirector10% Owner
Officer (give title below)Other (specify below)
2a. Foreign Trading Symbol
3. Date of Earliest Transaction (Month/Day/Year)
09/19/2025
6. Individual or Joint/Group Filing (Check Applicable Line)
XForm filed by One Reporting Person
Form filed by More than One Reporting Person
4. If Amendment, Date of Original Filed (Month/Day/Year)

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3) 2. Transaction Date (Month/Day/Year)2A. Deemed Execution Date, if any (Month/Day/Year)3. Transaction Code (Instr. 8) 4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5) 5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4) 6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) 7. Nature of Indirect Beneficial Ownership (Instr. 4)
CodeVAmount(A) or (D)Price
Common Stock01/24/2026M1,875A(1)14,625D
Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned
(e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3) 2. Conversion or Exercise Price of Derivative Security 3. Transaction Date (Month/Day/Year)3A. Deemed Execution Date, if any (Month/Day/Year)4. Transaction Code (Instr. 8) 5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5) 6. Date Exercisable and Expiration Date (Month/Day/Year)7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4) 8. Price of Derivative Security (Instr. 5) 9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4) 10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) 11. Nature of Indirect Beneficial Ownership (Instr. 4)
CodeV(A)(D)Date ExercisableExpiration DateTitleAmount or Number of Shares
Stock Option (Right to Buy)$0.1509/19/2025A179,854 (2)09/19/2035Common Stock179,854$0179,854D
Restricted Stock Units(1)01/24/2026M1,875 (3) (3)Common Stock1,875$01,875D
Explanation of Responses:
1. Each restricted stock unit ("RSU") represents a contingent right to receive one share of the Issuer's common stock.
2. The stock option vested as to 1/36 on October 31, 2025, with the remaining options vesting thereafter in equal consecutive monthly increments for 35 months, subject to the Reporting Person's continuous service to the Issuer through the applicable vesting date.
3. The RSUs vested as to 50% on the first anniversary of January 24, 2024 and the remaining amount vested in two equal annual installments thereafter.
/s/ Sumit Aggarwal, Attorney-in-Fact05/08/2026
** Signature of Reporting PersonDate
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
* Form 4: SEC 1474 (03-26)

FAQ

What did Eloxx (ELOX) director Steven D. Rubin report on this Form 4?

Director Steven D. Rubin reported equity compensation activity, not open-market trades. He exercised 1,875 restricted stock units into common shares and disclosed holdings of 14,625 common shares, 1,875 RSUs, and 179,854 stock options granted at a $0.15 exercise price.

How many Eloxx (ELOX) shares does Steven D. Rubin hold after the reported transactions?

After exercising restricted stock units, Steven D. Rubin directly holds 14,625 shares of Eloxx common stock. He also retains 1,875 RSUs and 179,854 stock options, providing additional potential equity exposure if vesting and exercise conditions are satisfied over the disclosed vesting schedule.

What stock option grant did Steven D. Rubin receive from Eloxx (ELOX)?

Steven D. Rubin received a grant of 179,854 Eloxx stock options on September 19, 2025 at a $0.15 exercise price. The options vest 1/36 on October 31, 2025, with remaining options vesting monthly over 35 months, and expire on September 19, 2035.

How do the reported RSUs for Eloxx (ELOX) director Steven D. Rubin vest?

Each RSU represents a right to receive one Eloxx common share. The RSUs vested 50% on the first anniversary of January 24, 2024, with the remaining amount vesting in two equal annual installments thereafter, aligning equity compensation with continued service to the company.

Were Steven D. Rubin’s reported Eloxx (ELOX) transactions open-market buys or sells?

The reported transactions were not open-market buys or sells. They reflect an RSU conversion into 1,875 common shares and a previously granted stock option award, both forms of equity compensation rather than discretionary trading in Eloxx stock on the public market.